Page 217 - Read Online

Table 1: Recommendation of treatment as per American hematological disorders. In: Turner TL, editor. Perinatal
Society of Hematology 2011 Hematological Problems. Chichester: John Wiley and Sons
Ltd.; 1991. p. 23-38.
Prior to conception No negative data on imatinib in 4. Rothman LA, Cohen CJ, Astarloa J. Placental and fetal
male patients involvement by maternal malignancy: a report of rectal
IFN for male and female patients carcinoma and review of the literature. Am J Obstet Gynecol
First and second trimester Low-dose IFN 3 million IU three 1973;116:1023-34.
times /week, adjusted to cell counts 5. Lichtman M, Liesveld J. Acute Myelogenous Leukemia.
and tolerability Williams Hematology. 6th ed. New York: McGraw-Hill; 2001.
p. 1047-84.
Avoid PEG-IFN, leukapheresis in
case of high leukocytes 6. Doll DC, Ringenberg QS, Yarbro JW. Management of cancer
Third trimester IFN during pregnancy. Arch Intern Med 1988;148:2058-64.
7. Buekers TE, Lallas TA. Chemotherapy in pregnancy.
Hydroxyurea if loss of Obstet Gynecol Clin North Am 1998;25:323-9.
hematologic response 8. Zuazu J, Julia A, Sierra J, Valentin MG, Coma A, Sanz MA,
Breast feeding period IFN Batlle J, Flores A. Pregnancy outcome in hematologic
IFN: Interferon; PEG: Pegylated malignancies. Cancer 1991;67:703-9.
9. Ault P, Kantarjian H, O’Brien S, Faderal S, Beran M,
check for loss of molecular response. During lactation, Rios M, Koller C, Giles F, Keating M, Talpazand M, Cortes J.
[17]
TKI is contraindicated, if the patient is on TKI; then Pregnancy among patients with chronic myeloid leukemia
treated with imatinib. J Clin Oncol 2006;24:1204-8.
she should avoid breastfeeding. In our patient, she 10. Pye SM, Cortes J, Ault P, Hatfi eld A, Kantarjian H, Pilot R,
was on chemotherapy with either hydroxyurea IFN or Rosti G, Apperley JF. The effects of imatinib on pregnancy
imatinib for the last 12 years. Successful pregnancy after outcome. Blood 2008;111:5505-8.
continuous chemotherapy for 12 years is very rare. Our 11. Cortes J, O’Brien S, Ault P, Borthakur G, Jabbour E,
patient was diagnosed as CML at age 11, which is also Bradley-Garelik B, Debreczeni K, Yang D, Liu D,
quite uncommon. Her young age may have contributed Kantarjian H. Pregnancy outcomes among patients with
to a better clinical outcome. chronic myeloid leukemia treated with dasatinib. Blood
2008;112:abstract 3230.
The treatment of leukemia in pregnancy poses a 12. Cole S, Kantarjian H, Ault P, Cortés JE. Successful completion
signifi cant challenge for medical oncologists as well of pregnancy in a patient with chronic myeloid leukemia
as patients. Our patient received all possible treatment without active intervention: a case report and review of the
literature. Clin Lymphoma Myeloma 2009;9:324-7.
options and achieved a long-term remission. Although 13. Conchon M, Sanabani SS, Serpa M, Novaes MM, Nardinelli L,
this experience is limited to a single patient, data on this Ferreira PB, Dorliac PE, Bendit I. Successful pregnancy and
patient indicate that CML management during pregnancy delivery in a patient with chronic myeloid leukemia while on
may be individualized based on a balance between dasatinib therapy. Adv Hematol 2010;2010:136252.
relative risks and benefi ts to the patient and fetus. 14. Novartis Pharmaceuticals Corporation. Tasigna (nilotinib)
[package Insert]. East Hanover: Novartis Pharmaceuticals
Financial support and sponsorship Corporation; 2007. Available from: https://www.pharma.
us.novartis.com/product/pi/pdf/tasigna.pdf. [Last accessed on
Nil. 2015 Sep 30].

Confl icts of interest 15. Conchon M, Sanabani SS, Bendit I, Santos FM, Serpa M,
Dorliac-Llacer PE. Two successful pregnancies in a woman
There are no confl icts of interest. with chronic myeloid leukemia exposed to nilotinib during the
fi rst trimester of her second pregnancy: case study. J Hematol
References Oncol 2009;2:42.
16. Hochhaus A. Educational session: managing chronic myeloid
1. Rowley JD. Letter: A new consistent chromosomal leukemia as a chronic disease. Hematology Am Soc Hematol
abnormality in chronic myelogenous leukaemia identifi ed Educ Program 2011;2011:128-35.
by quinacrine fl uorescence and Giemsa staining. Nature 17. Kuwabara A, Babb A, Ibrahim A, Milojkovic D, Apperley J,
1973;243:290-3. Bua M, Reid A, Foroni L, Rezvani K, Goldman J, Marin D.
2. Hensley ML, Ford JM. Imatinib treatment: specifi c issues Poor outcome after reintroduction of imatinib in patients with
related to safety, fertility, and pregnancy. Semin Hematol chronic myeloid leukemia who interrupt therapy on account
2003;40:21-5. of pregnancy without having achieved an optimal response.
3. Slade R, James DK. Pregnancy and maternal malignant Blood 2010;116:1014-6.

210 Journal of Cancer Metastasis and Treatment ¦ Volume 1 ¦ Issue 3 ¦ October 15, 2015 ¦